erlotinib hydrochloride has been researched along with casein kinase ii in 3 studies
| Studies (erlotinib hydrochloride) | Trials (erlotinib hydrochloride) | Recent Studies (post-2010) (erlotinib hydrochloride) | Studies (casein kinase ii) | Trials (casein kinase ii) | Recent Studies (post-2010) (casein kinase ii) |
|---|---|---|---|---|---|
| 4,353 | 786 | 3,033 | 3,268 | 5 | 1,299 |
| Protein | Taxonomy | erlotinib hydrochloride (IC50) | casein kinase ii (IC50) |
|---|---|---|---|
| Serine/threonine-protein kinase Sgk1 | Homo sapiens (human) | 3.57 | |
| Ribosyldihydronicotinamide dehydrogenase [quinone] | Homo sapiens (human) | 0.484 | |
| Casein kinase II subunit alpha | Rattus norvegicus (Norway rat) | 0.14 | |
| Casein kinase II subunit alpha' | Homo sapiens (human) | 2.23 | |
| Cyclin-A2 | Homo sapiens (human) | 2.38 | |
| Cyclin-dependent kinase 2 | Homo sapiens (human) | 2.38 | |
| Casein kinase II subunit beta | Homo sapiens (human) | 2.23 | |
| Casein kinase II subunit beta | Rattus norvegicus (Norway rat) | 0.14 | |
| Casein kinase II subunit alpha | Homo sapiens (human) | 2.23 | |
| Cyclin-A1 | Homo sapiens (human) | 2.38 | |
| Dual specificity tyrosine-phosphorylation-regulated kinase 1A | Homo sapiens (human) | 0.26 | |
| Casein kinase II subunit alpha 3 | Homo sapiens (human) | 0.14 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Anderes, K; Bliesath, J; Bunag, D; Drygin, D; Ho, C; Huser, N; Lim, JK; O'Brien, SE; Omori, M; Proffitt, C; Rice, WG; Ryckman, DM; Siddiqui-Jain, A; Streiner, N | 1 |
| Choi, CM; Choi, YJ; Chun, YJ; Kim, CH; Kim, SY; Kim, WS; Lee, JC; Rho, JK; So, KS; Song, JS | 1 |
| Brown, B; Molloy, MP; Neilson, KA; Semaan, C | 1 |
3 other study(ies) available for erlotinib hydrochloride and casein kinase ii
| Article | Year |
|---|---|
Combined inhibition of EGFR and CK2 augments the attenuation of PI3K-Akt-mTOR signaling and the killing of cancer cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Casein Kinase II; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Mice; Naphthyridines; Neoplasms; Phenazines; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; TOR Serine-Threonine Kinases | 2012 |
Autophagosome-mediated EGFR down-regulation induced by the CK2 inhibitor enhances the efficacy of EGFR-TKI on EGFR-mutant lung cancer cells with resistance by T790M.
Topics: Apoptosis; Autophagy; Casein Kinase II; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mutation; Naphthyridines; Phagosomes; Phenazines; Protein Kinase Inhibitors; Quinazolines | 2014 |
Pharmacological Inhibition of Casein Kinase 2 Enhances the Effectiveness of PI3K Inhibition in Colon Cancer Cells.
Topics: Casein Kinase II; Cell Line, Tumor; Cell Proliferation; Cell Survival; Colonic Neoplasms; Drug Synergism; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; HT29 Cells; Humans; Imidazoles; Indazoles; MAP Kinase Signaling System; Mutation; Naphthyridines; Oximes; Phenazines; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Mas; Proto-Oncogene Proteins B-raf; Sulfonamides | 2018 |